Genentech Discloses Promising Data on Perjeta in Neoadjuvant Treatment For Specific Breast Cancer Patients
News
Genentech, a member of the Roche Group, recently announced encouraging results on its Phase II NeoSphere trial evaluating Perjeta (pertuzumab) as a neoadjuvant (pre-surgery) treatment in specific early breast cancer ... Read more